Treatment Program for Anemia in AIDS Patients - Tabular View

Tracking Information
First Received Date ^ICMJE	November 2, 1999
Last Updated Date	June 23, 2005
Start Date ^ICMJE
Primary Completion Date
Current Primary Outcome Measures ^ICMJE
Original Primary Outcome Measures ^ICMJE
Change History	Complete list of historical versions of study NCT00002022 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE
Original Secondary Outcome Measures ^ICMJE

Descriptive Information
Brief Title ^ICMJE	Treatment Program for Anemia in AIDS Patients
Official Title ^ICMJE	Treatment Program for Anemia in AIDS Patients
Brief Summary	The objective of the Eprex (erythropoietin) Treatment Program is to provide erythropoietin for the treatment of anemia in AIDS patients.
Detailed Description
Study Phase
Study Type ^ICMJE	Interventional
Study Design ^ICMJE	Treatment, Dose Comparison
Condition ^ICMJE	HIV Infections Cytopenias
Intervention ^ICMJE	Drug: Epoetin alfa
Study Arms / Comparison Groups
Publications *
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE
Completion Date
Primary Completion Date
Eligibility Criteria ^ICMJE	Exclusion Criteria Co-existing Condition: Patients with the following are excluded: Life expectancy < 3 months. = or < grade 4 performance score. AIDS-related dementia. Uncontrolled hypertension. Acute symptomatic opportunistic infection or other AIDS-defining illness. Patients with the following are excluded: Life expectancy < 3 months. = or < grade 4 performance score. AIDS-related dementia. Uncontrolled hypertension. Acute symptomatic opportunistic infection or other AIDS-defining illness. Patients must have: A clinical diagnosis of AIDS. Hematocrit < 30 percent. Endogenous serum erythropoietin level = or < 500 U/ml. A life expectancy = or > 3 months. > Grade 4 performance score.
Gender	Both
Ages	12 Years and older
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	United States

Administrative Information
NCT ID ^ICMJE	NCT00002022
Responsible Party
Study ID Numbers ^ICMJE	004G, I88-083
Study Sponsor ^ICMJE	R W Johnson Pharmaceutical Research Institute
Collaborators ^ICMJE
Investigators ^ICMJE
Information Provided By	NIH AIDS Clinical Trials Information Service
Verification Date	February 1991
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP